Guggenheim Starts Verve Therapeutics (VERV) at Buy
Tweet
Share
E-mailGet Alerts VERV Hot Sheet
Price: $11.13 --0%
Rating Summary:
4 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
4 Buy, 8 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Guggenheim analyst Etzer Darout initiates coverage on Verve Therapeutics (NASDAQ: VERV) with a Buy rating and a price target of $84.00.
For an analyst ratings summary and ratings history on Verve Therapeutics click here. For more ratings news on Verve Therapeutics click here.
Shares of Verve Therapeutics closed at $46.00 yesterday.
You May Also Be Interested In
- Raymond James Starts SpyGlass Pharma (SGP) at Outperform
- Oppenheimer Starts Carriage Services (CSV) at Outperform
- Jefferies Starts Aehr Test Systems (AEHR) at Buy
Create E-mail Alert Related Categories
Hot New Coverage, New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
